AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis - LARVOL DELTA

Efficacy of Ivarmacitinib for Mild-to-Severe Alopecia Areata: A Case Series (EADV 2026) - "Dose escalation can achieve rapid therapeutic benefits in patients with an initially poor response. Larger real-world cohorts are warranted to further validate the efficacy and safety profile of ivarmacitinib, especially in mild-to-moderate AA populations."

Clinical • Alopecia • Immunology

Efficacy and Safety of Ivarmacitinib in Adult and Pediatric Patients with Alopecia Areata: A Real-World Analysis (EADV 2026) - "The mean SALT score change through week 12 Conclusions Ivarmacitinib demonstrated significant efficacy and a favorable safety profile in both adult and pediatric patients. The study is currently ongoing with continued follow-up and enrollment to gather longer-term data."

Clinical • Real-world • Real-world evidence • Alopecia • Immunology • Pediatrics

Real‑World Efficacy of Ivarmacitinib for Eyebrow and Eyelash Alopecia in Patients with Alopecia Areata (EADV 2026) - "Notably, eyebrow regrowth was generally superior to scalp regrowth. Conclusions In adult patients with alopecia areata, Ivarmacitinib demonstrates superior efficacy in treating eyebrow and eyelash alopecia compared with scalp alopecia, along with a favorable safety profile."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology • JAK1

Efficacy of Ivarmacitinib in Severe Alopecia Areata by Prior Treatment History: A Post-Hoc Analysis of a Phase 3 Trial (EADV 2026) - P3 | "This included 44 (20.0%) treated with systemic corticosteroids or immunosuppressants and 94 (42.7%) who received other therapies, primarily traditional herbal medicines, topical corticosteroids/immunosuppressants, and other dermatological preparations (e.g., topical minoxidil). J Am Acad Dermatol. 2026; 94(1):161-171."

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Concomitant Improvement of Severe Alopecia Areata and Vitiligo with the Selective JAK1 Inhibitor Ivarmacitinib: A Case Report (EADV 2026) - "Her medical history included papillary thyroid carcinoma status-post total thyroidectomy, with euthyroidism maintained by levothyroxine. Key clinical and laboratory data are summarized in Table1: Table1:Key clinical and laboratory data Conclusion This case demonstrates the successful concomitant treatment of severe AA and vitiligo with the selective JAK1 inhibitor ivarmacitinib, leading to near‑complete hair regrowth and significant vitiligo repigmentation within four months. The dual therapeutic response highlights the shared dependence of these two conditions on the JAK‑STAT signaling pathway and suggests that targeted JAK1 inhibition may represent a novel therapeutic option for patients with coexisting autoimmune dermatoses."

Case report • Clinical • Alopecia • Dermatology • Immunology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • Vitiligo • CD8

A Case Report: A 14-Year-Old Patient with Severe Alopecia Areata, Vitiligo, and Atopic Dermatitis Undergoing Ivarmacitinib Treatment (EADV 2026) - "Conclusion This case demonstrates that, in a real-world setting, ivarmacitinib exhibits significant efficacy and a reliable safety profile in a pediatric patient with severe alopecia areata. It also represents a suitable therapeutic option for patients with multiple concurrent IMIDs."

Case report • Clinical • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • Vitiligo

Ivarmacitinib Response Trajectories in Severe Alopecia Areata: A Post Hoc Analysis of Early, Gradual, Late, and Non‑Responder Subgroups Over 52 Weeks (EADV 2026) - "A shorter duration of the current AA episode and less-extreme baseline severity were associated with a higher likelihood of early response. Compared with 4 mg, the 8 mg dose increased the proportions of early and gradual responders, supporting 8 mg as the more effective dose to optimize clinical outcomes in severe AA."

Retrospective data • Alopecia • Immunology • JAK1

Rapid Efficacy of Ivarmacitinib in Promoting Scalp Hair, Eyebrow, and Eyelash Regrowth in Alopecia Areata: Chinese Single-Center Real-World Experience in Adults and Minors (EADV 2026) - "Ivarmacitinib emerges as a promising therapeutic option for AA. Updated data will be presented at the congress."

Clinical • Real-world • Real-world evidence • Alopecia • Immunology • JAK1

Efficacy of Ivarmacitinib in Adults with Severe Alopecia Areata Across Baseline Characteristics: A Post-hoc Analysis of a Phase 3 Trial (EADV 2026) - P3 | "J Am Acad Dermatol. 2026; 94(1):161-171."

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Ivarmacitinib treatment for cholinergic urticaria combined with atopic dermatitis: a report of two cases (EADV 2026) - "As of the data cut-off date, both patients remain on ivarmacitinib monotherapy, and no dose-limiting toxicities or serious adverse events have been reported. Figure 1 Clinical appearance of lesions from baseline to post-treatment assessment Conclusions Ivarmacitinib may offer a novel therapeutic avenue for cholinergic urticaria, supported by a favorable safety profile; however, these preliminary findings necessitate confirmation in larger-scale trials."

Clinical • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology • Urticaria

JAK inhibitors for the off-label treatment of two stevens-johnson syndrome cases: tofacitinib vs. ivarmacitinib (EADV 2026) - "The efficacy and risks of conventional therapies, including glucocorticoids, cyclosporine, and intravenous immunoglobulins, remain controversial. Conclusion A comparison of these two cases suggests that early initiation of a JAK inhibitor in combination with systemic corticosteroids may lead to a favorable outcome. Furthermore, ivarmacitinib appeared to be associated with a more rapid response than tofacitinib in these two cases; however, this observation warrants validation in future large-scale randomized controlled trials."

Clinical • Inflammation • Steven-Johnson Syndrome

Safety Profiles of Ivarmacitinib versus Tofacitinib in Vitiligo Treatment: A Retrospective Comparative Analysis (EADV 2026) - "Larger prospective studies are warranted to confirm these preliminary results. * The terms "increase" and "decrease" refer to levels above or below the normal range."

Retrospective data • Dermatology • Immunology • Vitiligo • CD8

Efficacy and Safety of lvarmacitinib, a Highly Selective JAK1 Inhibitor, in the Treatment of Non-Segmental Vitiligo (EADV 2026) - "Ivarmacitinib, a highly selective JAK1 inhibitor, remains under investigation for this condition...Although current data are limited by sample size and short follow-up, this study is actively ongoing with extended follow-up up to 12 weeks. Continued enrollment and longer-term data will be essential to confirm its clinical utility in non-segmental vitiligo."

Clinical • Dermatology • Dermatopathology • Immunology • Vitiligo

A retrospective observational study of oral ivarmacitinib and narrow-band ultraviolet-B in refractory progressive vitiligo (EADV 2026) - "Conclusions In summary, treatment with oral ivarmacitinib combined with NB-UVB could halt the progression of depigmented lesions and promote repigmentation in patients with vitiligo. Therefore, ivarmacitinib combined with NB-UVB may serve as an effective therapeutic regimen for refractory progressive vitiligo."

Observational data • Retrospective data • Dermatology • Immunology • Vitiligo

Twenty-four-week clinical outcomes and safety of oral ivarmacitinib in adults with stable non-segmental vitiligo: a real-world retrospective case series (EADV 2026) - "These findings should be interpreted as hypothesis-generating because of the small sample size, retrospective design, absence of a control group, and concomitant therapies in some patients. Further prospective controlled studies with longer follow-up are warranted."

Clinical data • Real-world • Real-world evidence • Retrospective data • Dermatology • Immunology • Vitiligo

OX40/OX40L Clinical Response Lag: A Systematic Review And Pharmacodynamic Analysis Of Amiltelimab, Rocatinlimab, And Ivarmacitinib. Proposing A New "Delayed Onset" Classification System For T-Cell Rebalancing Therapies In Atopic Dermatitis (EADV 2026) - "Introduction OX40/OX40L pathway inhibitors (amlitelimab, rocatinlimab, ivarmacitinib) are a newer class of T-cell rebalancing therapies for moderate-to-severe atopic dermatitis (AD). Unlike conventional biologics such as dupilumab, which show onset within 2–4 weeks, these agents consistently show a "response lag" of 8 to 16 weeks...Predictors of longer lag included baseline OX40L >450 pg/mL (hazard ratio for early response 0.41, p=0.003) and prior cyclosporine use (HR 0.58, p=0.01)...Lack of early response does not indicate treatment failure. An 18‑week minimum therapeutic trial is recommended before switching therapies."

Clinical • PK/PD data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • CD4 • TNFSF4

INSPIRE-T1D: JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Huijie Zhang

New P2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review. (PubMed, Front Med (Lausanne)) - "We report a case of a 35-year-old woman with a 9-month history of severe, progressive patchy alopecia that was refractory to baricitinib. This case highlights the diagnostic challenge posed by overlapping hair loss disorders and provides preliminary evidence for the potential therapeutic utility of ivarmacitinib in this clinical context. Furthermore, we sought further evidence from the literature to support the use of JAK inhibitors in lupus-associated alopecia."

Journal • Alopecia • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series. (PubMed, Clin Cosmet Investig Dermatol) - "This retrospective case series describes eight male patients with Hurley stage III HS who received tofacitinib (n=3), upadacitinib (n=4), or ivarmacitinib (n=1) after inadequate response to conventional therapies. However, responses and follow-up durations were heterogeneous, and the small sample size precludes comparisons between agents. Prospective controlled studies with standardized assessment timepoints and longer follow-up are needed to clarify efficacy, durability, and long-term safety."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Pain

Adebrelimab Plus Ivarmacitinib With or Without Chemotherapy as First-Line Treatment for Advanced NSCLC: A Phase 2 Trial (IASLC-WCLC 2026) - P2, P4 | "First-line pembrolizumab plus itacitinib (NCT03425006) resulted in a 12-week objective response rate (ORR) of 62% and a median progression-free survival (PFS) of 15.6 months in 23 patients with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%...Cohort B will additionally receive platinum-based doublet chemotherapy for 2 cycles (if pemetrexed is used for non-squamous NSCLC, it will be continued until disease progression or intolerable toxicity) since the initiation of adebrelimab treatment...The 95% confidence intervals (CIs) of ORR and DCR will be calculated using the Clopper-Pearson method. Median survival will be estimated using the Kaplan-Meier method, and the corresponding 95% CIs will be calculated using the Brookmeyer-Crowley method."

Clinical • IO biomarker • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • CD8 • EGFR • MET • ROS1

Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety. (PubMed, Drug Des Devel Ther) - "Peficitinib has the most mature evidence base, including Phase 3 efficacy, radiographic protection, long-term extension data, and pooled safety analyses. Ivarmacitinib has phase 3 and exploratory MRI data, whereas the phase 3 trial of TLL-018 has reached primary completion, with sponsor-reported topline findings available but complete results not yet published. CPL409116/CPL'116 remains supported by limited Phase 2 evidence. Decernotinib represents an informative historical proof-of-concept programme. Overall, no emerging agent has yet demonstrated a reproducible advantage over established JAK inhibitors in sustained remission, structural preservation, difficult-to-treat disease, or overall benefit-risk balance. Future development should prioritise active comparators, prespecified structural outcomes, prolonged safety assessment, and prospectively validated treatment-specific biomarkers."

Journal • Review • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy and Health-Related Quality of Life Improvements with Ivarmacitinib in Biological DMARD-Experienced Rheumatoid Arthritis Patients: A Post-Hoc Analysis from a Phase III Trial (ACR Convergence 2026) - No abstract available

Clinical • HEOR • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy of Ivarmacitinib in Vitiligo Treatment: A Retrospective Analysis of 7 Cases (EADV 2026) - No abstract available

Retrospective data • Dermatology • Immunology • Vitiligo

52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo-controlled period. Because the extension phase had no placebo control after Week 16, long-term efficacy findings should be interpreted as descriptive."

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - P2/3 | N=294 | Not yet recruiting | Sponsor: Chinese SLE Treatment And Research Group

Head-to-Head • New P2/3 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus